Targeting the Biophysical Properties of the Myeloma Initiating Cell Niches: A Pharmaceutical Synergism Analysis Using Multi-Scale Agent-Based Modeling

Jing Su1, Le Zhang2,3, Wen Zhang4, Dong Song Choi5, Jianguo Wen5, Beini Jiang6, Chung-Che Chang7*, Xiaobo Zhou1*

1 Department of Radiology, The Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, 2 College of Computer and Information Science, Southwest University, Chongqing, People's Republic of China, 3 School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, New York, United States of America, 4 Jan and Dan Duncan Neurological Research Institute, Baylor College of Medicine, Houston, Texas, United States of America, 5 Department of Pathology, The Methodist Hospital Research Institute, Weil Cornell Medical College, Houston, Texas, United States of America, 6 Department of Mathematical Sciences, Michigan Technological University, Houghton, Michigan, United States of America, 7 Department of Pathology, Florida Hospital, University of Central Florida, Orlando, Florida, United States of America

Abstract

Multiple myeloma, the second most common hematological cancer, is currently incurable due to refractory disease relapse and development of multiple drug resistance. We and others recently established the biophysical model that myeloma initiating (stem) cells (MICs) trigger the stiffening of their niches via SDF-1/CXCR4 paracrine; The stiffened niches then promote the colonogenesis of MICs and protect them from drug treatment. In this work we examined in silico the pharmaceutical potential of targeting MIC niche stiffness to facilitate cytotoxic chemotherapies. We first established a multi-scale agent-based model using the Markov Chain Monte Carlo approach to recapitulate the niche stiffness centric, oncogenic positive feedback loop between MICs and myeloma-associated bone marrow stromal cells (MBMSCs), and investigated the effects of such intercellular chemophysical communications on myeloma development. Then we used AMD3100 (to interrupt the interactions between MICs and their stroma) and Bortezomib (a recently developed novel therapeutic agent) as representative drugs to examine if the biophysical properties of myeloma niches are drugable. Results showed that our model recapured the key experimental observation that the MBMSCs were more sensitive to SDF-1 secreted by MICs, and provided stiffer niches for these initiating cells and promoted their proliferation and drug resistance. Drug synergism analysis suggested that AMD3100 treatment undermined the capability of MICs to modulate the bone marrow microenvironment, and thus re-sensitized myeloma to Bortezomib treatments. This work is also the first attempt to virtually visualize in 3D the dynamics of the bone marrow stiffness during myeloma development. In summary, we established a multi-scale model to facilitate the translation of the niche-stiffness centric myeloma model as well as experimental observations to possible clinical applications. We concluded that targeting the biophysical properties of stem cell niches is of high clinical potential since it may re-sensitize tumor initiating cells to chemotherapies and reduce risks of cancer relapse.

Citation: Su J, Zhang L, Zhang W, Choi DS, Wen J, et al. (2014) Targeting the Biophysical Properties of the Myeloma Initiating Cell Niches: A Pharmaceutical Synergism Analysis Using Multi-Scale Agent-Based Modeling. PLoS ONE 9(1): e85059. doi:10.1371/journal.pone.0085059

Editor: Persio Dello Sbarba, Università degli Studi di Firenze, Italy

Received July 8, 2013; Accepted November 21, 2013; Published January 27, 2014

Copyright: © 2014 Su et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors thank the funding resource: NIH/NLM 5R01LM010185-04. One of the authors, Dr. Le Zhang, is currently supported by the Natural Science Foundation of China under Grant No. 61372138. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: Le.Zhang@URMC.Rochester.edu (LZ); C.Jeff.Chang.MD@Flhosp.org (CC); xzhou@wakehealth.edu (XZ)

Introduction

Multiple myeloma (MM) and other tumors have a small population of tumor initiating (stem) cells that retain key stem cell properties including self-renewal and tumorigenesis [1–13]. Recent reports [3,4] showed that a small population of CD138−negative B cells with “side population” characteristics present in myeloma. These cells have clonogenic potential in vitro and, when engrafted into immunodeficient/nobese diabetes (SCID/ NOD) mice, can initiate de novo myeloma lesions of bulk of CD138+ cells in both primary and secondary transplant assays. Additionally, these myeloma initiating cells (MICs) have shown higher resistance to chemotherapeutic agents and thus are more likely to survive despite therapies [1–10]. These findings have led to the hypothesis that MICs survive chemo- and radio-therapies, regenerate the bulk of tumors, and thus cause the disease relapse. This idea is consistent with the clinical observation that disease relapse in multiple myeloma patients is common even if patients are treated with new therapeutic agents that can initially result in complete clinical responses [14–16]. Understanding and controlling MIC drug resistance is critical to the development of new therapies for the cure of myeloma.

Our group pioneered the research of the roles of biophysical properties in blood cancers and established the mechanism of the MIC-stroma positive feedback loop [17,18]. Previous studies on the interactions between BMSCs and myeloma cells, especially...
MICs, have predominantly focused on biochemical communications such as the stimuli of growth factors, cytokines and chemotactic via paracrine signaling [19]. However, recent studies in solid tumors have indicated that a critical stage of the malignant transformation journey of cancer cells involves marked alterations in the biomechanical phenotype of the cell and its surrounding microenvironment [20,21]. Indeed, it has been suggested that targeting the microenvironments (the “niches”) of the tumor stem cell could result in a reduction of the tumor burden [22–24]. Bone marrow stromal cells (BMSCs), one of the major cellular components in the MIC niches, are in close contact with MICs, and hence the biomechanical properties of BMSCs, besides chemical communications, also influence the local microenvironment of MICs and hence MIC fates. We have recently demonstrated that Myeloma-associated BMSCs (MBMSCs) from patients are much “stiffer” (higher Young’s modulus level) and more contractile than Normal BMSCs (NBMSCs). Hydrogels are widely used to mimic the in vivo cellular microenvironments [25,26], so we have utilized hydrogels of various stiffness levels to investigate the impact of such biophysical property on MIC-driven myeloma development. We have shown that stiffer hydrogels support colony formation and adherence of MICs better than softer hydrogels, suggesting that myeloma BMSCs provide myeloma cell-friendly microenvironments for MICs via exerting biomechanical forces [17,18]. We also have demonstrated that MICs over-secrete SDF1 than mature myeloma cells and that treatment of CXCR4 inhibitor, AMD3100, leads to decreased adherence of MICs to MBMSCs, undermined colony formation potential of MICs, and better in vitro and in vivo drug efficacy of Bortezomib (BZM). These discoveries were also consistent with other reports [27].

With the perspective that the biophysical properties of MIC niches in bone marrow may be a promising drug candidate, there is an urgent need to develop mathematical models and tools to estimate drug effects on MICs within the context of their niches during when screening and evaluating drug candidates. Currently pharmaco-industries use the killing efficiency of the bulk tumor as drug screening criterion. Such practices overlook the importance of MICs cell microenvironments contributing to the common failure of translating promising drug candidates discovered in screening into clinical usage. However, mathematical models that involve the cancer initiating (stem) cells and their niches are still rare, except for few examples [28–30] including our recent work [31].

Modeling the dynamics of the MIC-derived myeloma lineage is crucial for associating the abnormality at cellular level with the features of the myeloma pathogenesis and pathophysiology at tissue level. We recently developed a myeloma lineage model [31] to systematically analyze the myeloma lineage development and experimentally monitor the major sub-populations in the lineage. Briefly, cells involved in the myeloma lineage were classified as myeloma initiating cells (MICs), myeloma progenitor cells (PCs), and matured myeloma cells (MMs). These three sub-populations were experimentally distinguishable by dual-staining for the expression of plasma cell surface markers CD138 and for side population (SP) using Hoechst staining, each showed unique features related with lineage sub-populations. MICs, recognized by SP staining and negative CD138 staining (SP/CD138−), showed unlimited renewal capability, potential to initiate and fully re-establish the whole myeloma lineage, and enhanced drug resistance. PCs, defined as the non-SP and negative CD138 expression (non-SP/CD138−) population, were only able to passage for limited rounds before beginning to express CD138 and losing the key PG character. The CD138+ sub-population, which was of 90% to 95% of the total myeloma population, was classified as the MMs and exhibit very limited proliferation capability. In this work we used similar definitions except further distinguishing terminal MMs (TMMs) that could no longer proliferate from those that still could divide (MMs).

To comprehensively illustrate the interaction between the myeloma initiating cells and their niches and to develop effective drug treatment, the following key questions need special attention: (1) How do BMSCs, MICs, myeloma progenitor cells (PC), matured myeloma cells (MMs) and terminal MMs (TMMs) communicate in MIC niches? (2) How do the biomechanical phenotypes of BMSC, in terms of cell stiffness and contractibility, modulate MIC’s growth and fates? (3) How do MIC growth and differentiation drive the development of myeloma? (4) How do the molecular level intracellular features of MICs and their stromal counterpart, BMSCs, contribute to the tissue level 3D cancer growth via the intercellular cell-to-cell interactions? And (5) How does the interaction between tumor cells and their niches change the drug treatment effect?

To address these questions, in this study we developed a 3D multi-scale agent-based model (ABM) using Markov Chain Monte Carlo approaches [32] to study the role of tumor-stroma interactions in multiple myeloma tumor progress. The system was classified into three levels: the intracellular, the intercellular, and the tissue level. Their relations were conceptually defined as “interfaces” among these levels. The agent-based model integrates events of multiple spatial and temporal scales. (1) Spatial scales: Intracellular signaling pathways were encapsulated into each cell type to determine the BMSC intercellular biomechanical phenotype (cell stiffness) or tumor cell behaviors (migration or proliferation). Cancer cells competed for the best location in 3D extracellular matrix to migrate or proliferate regarding to the change of BMSC cell’s stiffness and sensitivity of chemoattractant (SDF1). In turn, chemoattractant cues at the tissue level triggered intracellular signaling pathways inside cells via the agent interfaces (receptors), and the resultant feedbacks were the changes of either cells’ properties (change of cell stiffness or sensitivity to outside stimuli) or behaviors (secretion of chemoattractant, proliferation, differentiation, apoptosis, or migration). (2) Temporal scales: The model covered minute-to-hour-level signaling dynamics; day-level cell division, apoptosis, and local migration; week-level drug responses; and month-level tumor growth.

The spatial characteristics of the 3D myeloma cell distributions was described by the local cell metrics [33] we previously developed and the corresponding parameters estimated using the 3D cell co-culture system levitated by magnetic field and nanoshuttles [34].

Results

Model development

We established an agent-based multi-scale model to simulate the development of myeloma in various bone marrow microenvironments in three-dimensional space, and validated the model with experimental data. The central hypotheses are: 1) MICs drive the development of multiple myeloma; and 2) the SDF1-centric biophysical and chemical positive feedback loop boosts MIC growth and colonogenesis, and protects MICs from drug treatments. As shown in Figure 1, myeloma development was simulated at intracellular, intercellular, and tissue levels. In this model we included five types of cells which were represented by five types of agents of encapsulated intracellular signaling events and interfaces through which these agents communicated with their microenvironments:
(1) Bone marrow stromal cell (BMSC) agent: This agent modeled the 3D reticular network formed by BMSCs. BMSCs changed its biophysical stiffness by cell contraction in response to SDF-1 hints in microenvironment and thus altered the three-dimensional distribution of bone marrow stiffness;

(2) Myeloma initiating cell (MIC) agent: This agent represented myeloma stem cells enriched by side population staining [4,35]. MIC sensed the stiffness of its microenvironment and accordingly modulated its proliferation, differentiation, apoptosis, and drug resistance;

(3) Progenitor cell (PC) agent: This agent simulated the expansion of tumor tissue from MICs with given passenger limits. This type of cells was lack of clear surface markers;

(4) Mature multiple myeloma cell (MM) agent: The mature multiple myeloma cells which presented clear surface markers (for example CD138) while still proliferating; and

(5) Terminal myeloma cell (TMM) agent: modeling terminal MM cells which can no longer proliferate.

Please note that although mathematically PC, MM, and TMM can be lumped into one agent, each of them have unique biological behaviors (such as apoptosis rates) and can be experimentally measured by flow cytometry. Therefore we kept them distinguished for better understanding the simulation results for future experimental validations, and for clinical applications.

At the intercellular level the communication among agents were simulated by the biomechanical model representing the MIC-BMSC positive feedback loops and the myeloma lineage model illustrating the dynamics of different myeloma populations. Interactions between BMSC and MIC were: (a) MICs secreted SDF1 into the neighborhood extracellular matrix. The diffusion of SDF1 in the tissue defined the biochemical microenvironment in bone marrow. The BMSCs contracted according the paracrine SDF1 in their neighborhood and altered the biophysical properties of the bone marrow. MICs sensed and preferably attached to stiffer BMSCs. When attached, stiffer BMSCs boosted proliferation and self-renewal of MICs, and thus promoted the expansion of both MIC and myeloma, and drove sustainable multiple myeloma cancer growth. Stiffer BMSCs also protected MICs from the treatment of cytotoxic drugs.

At the tissue level, the SDF1 profile defined by MIC paracrine and diffusion and the drug concentration defined by the administration of chemotherapeutics determined the biochemical microenvironment in bone marrow, the tissue stiffness defined by BMSC contraction determined the biophysical microenvironment, and myeloma proliferation and migration determined the cellular distribution in bone marrow.

Multiple myeloma cells at different stage of differentiation as defined above were initially seeded at the center of the bone marrow, 100 cells for each cell type, to mimic the initiation stage during myeloma spreading to new locations or after implantation into the bone marrow of animal models. Bortezomib (BZM) and AMD 3100 were used as the representatives of cytotoxic drugs and inhibitors against MIC-BMSC interactions, respectively. After 200 hours of tumor seeding these two drugs were delivered intravenously into the simulated extracellular matrix at combinations of various doses to eliminate multiple myeloma cancer cells. The chemotherapy was scheduled that each cycle included a 400-hour treatment period followed by 500 hours rest (about 2 week treatment followed by 3 week rest), which was typical in clinics. In our experiments usually the animals were sacrificed and the outcome was examined 200 to 400 hours after the first treatment period or one month after tumor xenografting, so the simulation results of the first 600 to 1,000 hours (about one month) were shown. We only simulated the tumor responses to the first treatment cycle because multiple myeloma quickly develops drug resistance and therefore elimination of all MICs in the first treatment cycle is crucial. Parameters were directly determined or indirectly inferred based on our previous experimental results.

Figure 1. A sketch of ABM model.
[17,18,36], or set according to the best of our knowledge of multiple myeloma, and were summarized in Table S1 and Table S2 in Supporting Information.

To reduce the computational cost the diffusion of the two drugs in bone marrow was assumed to be instantly. This assumption is valid since the myeloma-enriched regions in bone marrow are well vascularized and the diffusion of small molecule drugs is significantly faster comparing with either typical cell behaviors such as migration, proliferation, and apoptosis, or comparing with the diffusion of SDF-1.

Twelve dose levels (including level 0) for each drug and their full combinations were examined under both myeloma-associated BMSC (MBMSC) and normal BMSC (NBMSC) microenvironments, each condition simulated for 20 times. Time resolution (time step) was 2 hours. Totally 288 conditions was explored by 5,760 simulations using parallel computation on a Dell™ PowerEdge™ 850 server of 48 CPU cores.

Examples of model simulation results of MBMSCs disease development in bone marrow were visualized and compared with in vitro 3D levitated culture image in Figure 2. The tumor growth at different stage (100 hr vs. 500 hr post-initiation) as well as the associated variations of biophysical properties in bone marrow and activities of MICs were shown in Figure 2 A through D. As contrast, tumor and stiffness distributions under BZM treatment (dose of the 10th relative level) between 200 and 300 hr were demonstrated in Figure 2 E and F. Quiescent MICs were highlighted in blue and proliferating MICs in red. The details of biophysical stiffness in bone marrow were visualized by the sections in Figure 2 G. Stiffness was labeled in color, from blue to red with respect to the increase of stiffness. Since in vivo 3D imaging of BMSC contraction is yet unavailable, we co-cultured myeloma with BMSCs in vitro using the 3D levitation system to mimic the bone marrow microenvironment, and 4-day co-cultured tumor tissue was stained and 3D imaged by confocal microscopy (details see Methods section) and shown in Figure 2 H. BMSCs (white arrows) and myeloma cells (green arrows) were recognized by cell shapes according to F-actin staining (red) as well as nuclei staining (blue). The primed MBMSCs (yellow arrows) were recognized by the formation of stress fibers. The size of the experimentally cultured tumor at day 4 was about 266×492 μm, which was very close to the diameter of the infiltration frontier (about 460 μm) of the simulated results at time point 100 hr (Figure 2 A).

Details of the model can be found in the Methods section. Typical movies as Movie S1, S2, and S3 can be found in Supporting Information, and the corresponding simulation conditions in the caption of Figure 2.

Model validation

The simulation results of the agent-based model of myeloma growth under different biophysical microenvironments were compared with experimental results [18,36] to validate the model. The simulated MIC populations as well as the total tumor sizes under the NBMSC and MBMSC (Blue vs. red lines in Figure 3 A and B) after 4 weeks growth were consistent with experimental results [18] (Blue vs. red bars in Figure 3 A and B). Tumor also showed consistent BZM dose responses after 48 hr treatment in simulation and in experiments (blue vs. red lines, Figure 3 C). Data shown in Figure 3 were the mean values of the 20 simulations for every 20 hours (every 10 time steps).

Effects of MBMSCs in disease development

We first tuned the model to recapture experimental observations and explored the roles of myeloma-associated MBMSCs in disease development using the NBMSCs as controls. The simulation results of tumor growth and the comparison with experimental data were summarized in Figure 4 and Figure 3. The cell number of each tumor type during the first 600 hours (25 days) were shown for the NBMSC (Figure 4 A) or the MBMSC (Figure 4 B) case, and the MIC populations (Figure 3 A) as well as the total tumor sizes (Figure 3 B) were compared with our previously published experimental results. Tumor grew about 2.6 folds faster under MBMSC context, while the MIC population was 6.8 folds larger. Simulation results were consistent with experiments. The myeloma population in MBMSC was dominated by “younger” tumor cells such as progenitors comparing with the normal counterpart, which was dominated by terminal myeloma cells. Data shown in Figure 4 were also the mean values of the 20 simulations for every 20 hours (every 10 time steps).

Effects of MBMSCs on chemotherapy outcomes using BZM

To explore the drug resistance to chemotherapies and the risk of tumor relapse in MBMSC and NBMSC microenvironments, we simulated the first BZM treatment cycle at 11 dose levels covering two magnitudes. BZM was delivered 200 hours after tumor initiation and the treatments lasted for 400 hours. The dynamic of total tumor cells as well as MICs during the first 1000 hours were shown in Figure 5. After drug delivery, the tumor populations quickly dropped for both MBMSC and NBMSC (red and blue lines in Figure 5 a, respectively) cases. The drug efficacy, in terms of the elimination of myeloma population, was similar in both cases, and during the first treatment cycle the tumor cell number decreased to a very low level that were clinically not detectable. However, drug efficacy on MICs, a small portion of the tumor population, was significantly different. Medium dose of BZM treatment (the sixth level among all eleven) completely killed all the MICs in NBMSC-dominated bone marrow (Figure 5 b blue line), whereas a few MIC cells survived the chemotherapy in the MBMSC case (Figure 5 b red line) due to the drug resistance boosted by myeloma-associated stroma. The MIC-free tumor population kept degenerating till the cure of the disease, while in contrast the survived MICs re-initiate the myeloma and caused MIC-driven tumor relapse (Figure 5 a blue vs. red lines, time 600 to 1000 hr).

Two typical simulations were shown in Figure 5, and the rest were discussed in the following sections.

Inhibition of MIC-BMSC communications by AMD 3100 treatment

We then examined if the inhibition of MIC-BMSC communications could deprive MICs from the protection of their stroma and re-sensitize the tumor in the MBMSC context to chemotherapy. AMD 3100, a competitive inhibitor of SDF-1, was delivered at 11 levels crossing two magnitudes, either alone or with BZM, to myeloma growing with either myeloma-associated or normal BMSC stroma. The effects of medium AMD dose were visualized by two simulations in Figure 6 and the rest summarized in Figure 7. AMD-treated and AMD-free cases were denoted in solid and dashed lines, and the myeloma-associated and normal BMSC niches in red and blue colors, respectively. Consistent with Figure 3 (A) and (B) and Figure 5 (A) and (B), MBMSC niches promoted tumor growth (Figure 6 a red vs. blue dashed lines), MIC self-renewal (Figure 6 b red vs. blue dashed lines), and drug resistance (Figure 6 c red vs. blue dashed lines) driven by MICs (Figure 6 d red vs. blue dashed lines). Introduction of niche
inhibitor at moderate level alleviated all these effects (Figure 6A through D red vs. blue solid lines).

**Combined drug effects on both cases**

To evaluate if interrupting the MIC-BMSC communications has clinical potentials for multiple myeloma, we tested the combinatorial effects of the two representative drugs, AMD3100 and BZM. For each drug, 12 doses (0 as control and 11 levels from 0.1 x 10^-6 to 10^-6 in geometric sequence relative to the original dose) were selected and the full combinations of the two drugs were explored for drug efficacies. The default doses for each, denoted as 1 x, was defined as the minimum doses that, for BZM, eliminated all MICs in NBMSC case and, for AMD3100, deprived MBMSC support. Each combinatorial condition was simulated for 20 times at 400 time points for 5 cell types and SDF-1 concentration distributions, and totally 13,824,000 data sets were generated. The means of replicates were used for further analysis, and the synergistic effect maps were further smoothed with a two dimensional Gaussian kernel (σ = 2) for robust visualization.

Loewe combination index [37,38] (for an introduction and a guide of interpretation of Loewe combination index please refer to Figure S1 in the Supporting Information), defined according to the 50% MIC population reduction by the end of the two week chemotherapy (E50 at time point 600 hr), was utilized to evaluate the synergism of AMD3100 and BZM while treating myeloma in either NBMSC or MBMSC niche. We selected the total myeloma death rate as well as MIC death rate as the indicator of drug efficacy because as demonstrated in Figure 3 (first and second rows, respectively), MIC played essential role in post-treatment disease relapse [4]. The SDF-1/CXCR4 inhibitor showed on moderate effects on the efficacy of BZM when treating multiple myeloma developed in both normal and myeloma-associated bone marrow stromal cell microenvironments in terms of both the shrinkage of total tumor size (red contour lines in Figure 7 a and b, respectively) and the decrease of MIC populations (red contour lines in Figure 7 c and d, respectively). In contrast, dramatic synergistic effects of the two drugs were observed if the total elimination of MIC (E100) was used as the criterion for Loewe combination index in MBMSC cases (green contour lines in Figure 7 d) but not in NBMSC cases (green contour lines in Figure 7 c).

**Discussion**

This work previewed the druggability of the biophysical features of cancer stem cell niches, and cast new light on the strategies to overcome the drug resistance and relapse of multiple myeloma.

The central hypothesis of this work, that the positive feedback loop between MIC and MBMSC via SDF-1 paracrine and the increase of MBMSC niche stiffness promotes myeloma development and is responsible for drug resistance and cancer relapse, has been successfully realized in this multi-scale agent-based model. Figure 2 showed that MBMSCs close to MICs were primed and activated by SDF-1 secreted by MICs provided a stiffer microenvironment; such pro-oncogenic microenvironments, such as activated BMSCs, are responsible for drug resistance and cancer relapse. The tumor was subdivided into two types: a quiescent population in red while proliferating MICs in blue. The stiffness profiles (B and D) and the activities of MICs at early (100 hr, A and B) and later (500 hr, C and D) stages. (E and F) Tumor and stiffness distributions after BZM treatment at relative level 10 between time point 200 hr and 300 hr. The tumor infiltrating frontiers were labeled by brown isosurfaces, condensed tumor region in yellow, and quiescent MICs in blue while proliferating MICs in red. The stiffness distributions were labeled with isosurfaces, blue denoted lower stiffness and red higher stiffness. (G) The distribution of stiffness in myeloma-associated bone marrow stiffness 400 hr after initial myeloma seeding. (H) The distribution of myeloma cells and the activation of MBMSCs after 4 days 3D levitated culture. Blue: cell nuclei (stained with DAPI); red: F-actin fibers (stained with Alexa Fluor® 594 conjugated phallolidin); white arrow: MBMSCs; green arrow: myeloma cells; yellow arrow: activated BMSCs marked by the formation of stress fiber.

doi:10.1371/journal.pone.0085059.g002

**Figure 2. Simulation of myeloma development in three-dimensional bone marrow space.** The tumor growth (A and C) associated with the stiffness profiles (B and D) and the activities of MICs at early (100 hr, A and B) and later (500 hr, C and D) stages. (E and F) Tumor and stiffness distributions after BZM treatment at relative level 10 between time point 200 hr and 300 hr. The tumor infiltrating frontiers were labeled by brown isosurfaces, condensed tumor region in yellow, and quiescent MICs in blue while proliferating MICs in red. The stiffness distributions were labeled with isosurfaces, blue denoted lower stiffness and red higher stiffness. (G) The distribution of stiffness in myeloma-associated bone marrow stiffness 400 hr after initial myeloma seeding. (H) The distribution of myeloma cells and the activation of MBMSCs after 4 days 3D levitated culture. Blue: cell nuclei (stained with DAPI); red: F-actin fibers (stained with Alexa Fluor® 594 conjugated phallolidin); white arrow: MBMSCs; green arrow: myeloma cells; yellow arrow: activated BMSCs marked by the formation of stress fiber.
bone marrow (red lines in Figure 4 B versus A and the red vs. blue line in Figure 3 A) and thus drove the development of myeloma (Figure 3 A versus Figure 4 A and the red vs. blue line in Figure 3 B).

(3) Drug responses. The consistent dosing effects of BZM in terms of the shrinkage of tumor sizes between the model predictions and the experimental results (Figure 3 C) are strong evidence that the model has the capability to predict the drug responses of myeloma over a wide range of drug doses. AMD3100 deprived the support of niches to the expansion of MICs (Figure 6 solid vs. dashed lines). MICs showed drug resistance comparing with other myeloma cells [4,39], and such drug resistance was enhanced at the presence of MBMSCs (Figure 5 red vs. blue lines) [18].

The simulation results were consistent with our and others experimental observations, which provided a solid basis for the exploration of the synergistic effects of niche-specific drugs with cytotoxic chemotherapeutics. Please notice that although the in vitro 3D levitated culture has been known to be able to mimic in vivo microenvironment [34], the bone marrow contexts are still significantly different from the in vitro environments. Therefore, the highly consistent results between experimental data and simulation (Figure 2 A vs. H) only suggested that the simulation results were reasonable and the model is sufficient for piloting in silico study.

In vivo assays of myeloma growth and drug responses are still necessary for parameter estimation, model training, and accurate predictions, which is future work and is beyond the focus of this study.

Loewe drug combination analysis [40,41] strongly suggested that inhibitors that block the MIC/BMSC communications are of high clinical potentials. Traditional Loewe combination analyses for chemotherapeutics often focus on the bulk tumor and use isobole at effect level 50 (E50) as standard index, which is convenient to monitor in animal models and clinical chemotherapy evaluations using micro-CT, bioluminescence, biopsy, and others. The elimination of the bulk tumor is also used as clinical index. However, this standard may not accurately reflect the drug efficacies against tumor-initiating-cell-driven tumor development. Capability to eliminate of all tumor initiating cells should be the key evaluation index. We thus defined the E100 isobole against MICs in our Loewe analysis and explored drug combinations that could successfully kill all MICs in the first treatment cycle. Simulations of the combination effects of the cytotoxic drug (BZM) and the niche-specific inhibitor (AMD3100) in myeloma-associated stroma, evaluated by the E100 isoboles against MICs, suggested strong synergistic effects (green lines in Figure 7 D). In contrast, E50 isoboles only indicated slight synergism between the two drugs (red lines in Figure 7 A through D). The control groups of the normal BMSC environments showed no responses to niche inhibitors (Figure 7 A and C), which further confirmed that AMD3100 did not directly affect MICs and the strong synergism observed in the MBMSC cases were due to the interruption of the MIC-BMSC communication. Such dramatic difference suggested that for TIC-driven tumors drug effects should be estimated in terms of the total eradication of TICs, and E100 isoboles against
TICs provide a more sensitive evaluation of the effectiveness of treatments. Specifically, for the multiple myeloma treatment evaluation and relapse risk estimation, our results highly suggested using the percentage of MIC population in patient bone marrow aspirate by either side population staining or surface marker immuno-staining (e.g. CD138) and flow cytometry.

Simulations also suggested that niche-specific drugs are strongly synergistic with tumor-specific cytotoxic drugs and re-sensitize myeloma to the otherwise resistant drugs. Cytotoxic drugs alone, though may efficiently kill the bulk of tumor, sometimes are not sufficient to demolish all TICs. As shown in Figure 7D, without the aid of AMD3100, BZM alone cannot extinguish all MICs and thus the disease will relapse soon after the chemotherapy (Figure 5). Taken together, the physical properties of the myeloma initiating cell niches is highly targetable, and the inhibitors of the interactions between cancer initiating cells and their stroma are promising co-drugs for traditional cytotoxic agents.

As a piloting research, this computational model is conceptual and some parameters were not directly estimated from experiment data, and some in vivo/clinical data and assays such as drug delivery and metabolism in patients may improve the accuracy of the predictions. However, we have omitted such details due to the following reasons: 1) To keep the focus of this work of the preliminarily modeling of a novel system. It is the first time to simulate the druggability of the biophysical properties, mainly the stiffness, of the bone marrow microenvironments and the major focus of this work is to establish a reliable model according to the

Figure 4. Profiles of simulation results. The growing trends of each tumor cell type under (A) NBMSC or (B) MBMSC environments were visualized.
doi:10.1371/journal.pone.0085059.g004

Figure 5. MIC-driven myeloma relapse after cytotoxic chemotherapy cycle. (A) The growing trends of tumor cells under MBMSC (red line) vs. NBMSC (blue) environments under drug treatments. (B) The growing trends of MICs under MBMSC (red line) vs. NBMSC (blue lines) environments under drug treatments. Drug treatment periods were highlighted with gray shade.
doi:10.1371/journal.pone.0085059.g005

Cancer Niche Stiffness Is a Promising Drug Target
relatively solid in vitro and animal experiment data. At this preliminary stage, it may be not ready to reach a precise predictive model for clinical treatment outcomes by including clinical data about the bone marrow properties as well as the underlying mechanisms (such as the diffusion processes of cytokines and the pharmacokinetics and the pharmacodynamics of bortezomib and AMD3100). 2) To address our major questions and reach conclusions with a reasonably simple model as possible. We have also simplified the detailed temporal profiles of drugs during chemotherapies and adjuvant therapies to constant levels as such detailed dynamic features, though important for providing optimal dosing in clinical treatments in the future, are not our focus at this stage. Indeed such simplification approaches are common in preliminary models of new systems and do not change the main conclusions of this work. 3) Furthermore, detailed molecular mechanisms of underlying signaling pathways are still missing before we can reach an accurate and more predictive model. The major goal of this work is to extend our current knowledge of how MICs modulate the physical properties of their niches to evaluating the therapeutic potential of targeting such remodeling process. For such purpose, the results of this work suggest using the complete eradication of TICs as drug efficacy index for TIC-driven cancers, emphasize the importance of targeting TIC niches, and encourage following-up investigations of niche-specific therapeutics.

Conclusions
It was the first time the three dimensional modeling of the biophysical properties of cancer stem cell niches and the therapeutic potential of targeting such mechanical features were attempted at the system level. Our in silico model successfully realized the bio-model of the MIC-BMSC chemical-physical

Figure 6. The effects of MIC-BMSC interaction inhibition on tumor growth and the outputs of cytotoxic chemotherapy. (A) The growing trends of tumor cells under MBMSC or NBMSC environment with or without niche inhibitor (AMD3100). (B) The growing trends of MIC cells under MBMSC or NBMSC environment with or without niche inhibitor (AMD3100). (C) The responses of myeloma tumor to cytotoxic drugs under MBMSC or NBMSC environment with or without niche inhibitor (AMD3100). (D) The responses of MICs to cytotoxic drugs under MBMSC or NBMSC environment with or without niche inhibitor (AMD3100). Myeloma-associated or normal BMSC niches were denoted in red or green color, and the effects of the niche inhibitors on tumor growth (A and B) or cytotoxic drug efficacy (C and D) were labeled in solid lines and their controls in dashed lines, respectively.
doi:10.1371/journal.pone.0085059.g006
positive feedback loop, and was capable to capture the key features of our experimental observations. Simulations suggest that the isoboles of drug capability to completely eliminate TICs in Loewe combination analysis can better predict treatment outcomes. Drug synergism analysis suggested that intervening the communications between myeloma initiating cells and their niches dramatically enhanced the efficacy of cytotoxic drugs against myeloma initiating cells, re-sensitized multiple myeloma to chemotherapies, and reduced risks of cancer relapse.

**Methods**

We defined five types of agents in the model to represent BMSC, MIC, PC, MM and TMM. We initialized the bone marrow as a cylinder 3D rectangular framework, with the tumor extracellular matrix (ECM) filled with BMSC agents distributed

---

**Figure 7. Synergy Effects of AMD3100 and BZM on total myeloma size (A and B) or on MICs (C and D) in NBMSC (A and C) or MBMSC niches (B and D).** Red lines indicate the E50 isoboles and green lines mark the E100 isoboles used in Loewe drug combination analysis. doi:10.1371/journal.pone.0085059.g007
evenly across the 3D ECM and the mixed MIC, PC, MM and TMM agents at the center of the bone marrow as a sphere. Such initiating cell ratios were according to the myeloma initiating cell hypothesis as well as our previous publications that the MICs can restore the whole myeloma population, including the composition ratios of myeloma cell types. This multi-scale modeling consisted of three scales: intracellular, intercellular and tissue scales, which were illustrated in Figure 1, Figure 8, and described in details in the following sections. The model was generally presented as pseudo-code and listed in Figure S6. Detailed flowcharts of each myeloma agent were illustrated in Figure S2 (for MIC agent), Figure S3 (for PC agent), Figure S4 (for MM agent), and Figure S5 (for TMM agent) in the Supporting Information. Parameters were determined according to our previous work as well as literature [17,18,36]. Mathematical and computational details are elaborated in Supporting Material.

**Stochastic Simulation of Cell Behaviors**

The Markov Chain Monte Carlo approach was used to simulate cell behaviors of each individual cell. As shown in Figure 8, cell behaviors were simulated by probability-based rule implementation. A cell sensed the hints of its neighborhood such as stiffness, SDF-1 level, and drug doses, processed them with imbedded pathways, and outputted the changes of probabilities of corresponding cell behaviors including cell proliferation rate, apoptosis rate, differentiation ratio, migration rate, contraction rate, and cytokine secretion rate. Cell decision was then determined by rolling a dice and compared with the probability of a given cell behavior. Cell behaviors in turn remodeled the properties of its niches. Details of each cell behavior for each type of cell agent as well as the corresponding rule was discussed in the following sections as well as the Supporting Information.

**Intracellular Scale**

Each BMSC agent encapsulated signaling pathway functions to determine its biomechanical phenotype switch, using an agent-specific Hill function [42] to describe the SDF-1/CXCR4 signaling pathway which regulated the local stiffness in response to the in-situ relative SDF1 concentration. The effects of the SDF1/CXCR4 inhibitor AMD3100 was simulated by competing with SDF1 for CXCR4 and thus reducing the effective SDF1 concentration.

Meanwhile, the responses of tumor agents (MIC, PC, MM, and TMM) to local ECM stiffness in terms of the possibilities of cells to enter the proliferation, apoptosis, and migration status were also simulated using Hill functions in similar ways. Cell decision-making process was defined by agent rules with such probabilities as the major inputs. The stochastic feature of the decision of an individual cell was realized by die casting simulation.

**Stem cell fate determination.** Once a MIC decided to enter cell cycle, its fates were further determined according to its microenvironment. A MIC either generate two MIC daughter cells, known as self-renewal, or to two PC cells, know as differentiation, or to one MIC and one PC, known as asymmetric division. The probability of each fate was determined using Hill functions, and the decision of each MIC agent was also realized by die casting simulation as mentioned above.

**Proliferation fates of PC and MM agents.** The fates of intermediate cell agents were determined by their passage ages as well as the probabilities of proliferation which represent the effects of cell neighborhood characters such as stiffness and cytokine concentration, and the current cell cycle status of the cells. PC agents were different from MM agents for their limited self-renewal capability. When maximum renewal limit reached, a PC agent differentiated to an MM agent. TMM agents did not proliferate. According to the myeloma initiating cell hypothesis, only MICs can self-renew and proliferate without limits, so defined is the LGN, which is the maximum passage number a PC cell can self-renew, or a MM cell can proliferate.

**Intercellular Scale**

Once a myeloma cell (MIC, PC, MM, or TMM) had determined its responses to the biomechanical properties of its microenvironment, it would proliferate, migrate, being quiescent, or undergo death, which were described in the intercellular scale.

**Migration.** A non-M-phase cell would migrate if it could find free space nearby. The migration was governed by rules representing space availability, stroma preference, migration speed, and stochastic effects using Hill functions and die-casting simulation as mentioned above.
Division of MIC, PC and MM agents. If M-phase cell found at least one free location within searching distance, it would divide, following the same migration rules but with a much smaller migration distance (i.e., slower migration speed) so the de novo daughter cells were always next to the parental cells. If no space was available, cells would remain in M-phase and try in next round.

Apoptosis. The decision-making of cell apoptosis was simulated using a pre-defined threshold for the apoptosis rate reflecting cell microenvironment, especially the local drug (BZM and AMD) concentrations and stiffness. The whole apoptosis process took about 20 hours. RPMI 8226 myeloma cell apoptosis rates under drug treatments were determined according to our previous study [36].

Tissue scales

In the tissue scale of this ABM, the secretion of SDF1 from MIC agents and the diffusion of SDF1 in the 3D ECM defined the dynamic 3D distribution of SDF1 concentration [43–45]. SDF1 was uniformly initialized at the start with Dirichlet boundary.

In summary, intracellular signaling pathways were encapsulated into each cell to determine either the BMSC intercellular biomechanical phenotype (cell stiffness) or tumor cells’ (MIC, PC and MM) behaviors (migration, differentiation, proliferation, or apoptosis). Cancer cells competed for the best location in 3D extracellular matrix to migrate or proliferate regarding to the change of BMSC cell’s stiffness and cell density. In turn, chemo-attractant cues (SDF1) at the tissue level triggered BMSC cell’s intracellular signaling pathways by receptors. And the resultant feedbacks were the changes of either cancer cells’ properties (change of BMSC cells’ stiffness) or behaviors of cancer cells (secretion of cytokines, proliferation, differentiation, apoptosis, or migration). Thus, the 3D dynamics of bone marrow stiffness and tumor growth were simulated at multiple temporal and spatial scales.

Materials and Methods

Myeloma cell model

We chose RPMI 8226, one of the most widely used human myeloma cell lines, as the myeloma cell model because it had been shown representative of key myeloma pathogenesis features of interest in this work. In vivo and in vitro evidence from our [17,18,36] and other research groups [3,4,46] suggested the clinical translational values [46] of the MICs from RPMI 8226, which re-capture major clinical myeloma stem cell characters such as drug resistance and initiating myeloma in bone marrow by generating the whole myeloma population, both of which are boosted by the positive feedback loops with their associated stroma cells in vivo the SDF-1/stiffness chemo-physical interactions. Specifically, RPMI 8226 has been shown to be representative among other frequently used human myeloma cell lines in terms of Bortezomib treatment responses [47,48].

Cell isolation and culture

Myeloma-associated and normal stroma cells were isolated and expanded from myeloma patients similarly as previously described [18], depending if they were diagnosed of bone marrow involved myeloma or not. Briefly, after lysis of red blood cells (RBC Lysis Solution, QIAGEN), patient bone marrow aspirate was cultured in MesenPRO RS™ medium (Invitrogen) in 5% CO₂ humidified atmosphere at 37°C for one week and unattached cells discarded. Attached MBMSC was expended under same culture conditions. Usage of these samples has been approved by the Institutional Review Board of The Methodist Hospital Research Institute (TMHRI). RPMI8226 multiple myeloma cell line was purchased from ATCC and cultured in RPMI 1640 medium (Mediatech) supplemented with 8% fetal bovine serum (Invitrogen) 100 units/ml penicillin and 100 mg/ml streptomycin (Life Technologies) at 37°C in 5% CO₂. This study was granted for Consent waiver by IRB.

Levitated 3D co-culture

Both MBMSC and RPMI8226 were treated with Nanoshuttle™ PL (n3D Biosciences) overnight per manufacturer’s instruction, MBMSC detached by slight trypsin treatment, mixed at 1:20 to 1:200 ratios (MBMSC:RPMI8226), transferred to Costar® 6 well Ultra Low Attachment plate (Corning) to reach about 400 cells per well, and immediately levitated using the 6-well Bio-Assembler™ Magnetic Drive (n3D Biosciences) and cultured in RPMI 1640 medium (Mediatech) as described before.

Staining and imaging

At day 4 the assembled MIC/MBMSC co-cultured tissue was collected, rinsed in PBS, fixed with 3.7% paraformaldehyde (Fisher) for 10 min, blocked with 1% bovine serum albumin (Fisher), and stained with Alexa Fluor® 594 phalloidin (Invitrogen) using 1:40 dilution for 30 min, followed by counter staining using 500 nM DAPI (Invitrogen) for 5 min, rinsed with DI water, and mounted with ProLong® Gold Antifade Reagent (Invitrogen) for imaging. The process was under the protection of the Magnetic Drive to avoid lost of cells. The Nikon AI Confocal Imaging System was used to image samples for DAPI and Alexa Fluor® 594 signals with optical slicing distance of 8 μM and the 3D images were reconstructed using NIS-Elements Microscope Imaging Software (Nikon).

Supporting Information

Figure S1 The Loewe drug combination analysis.

Figure S2 The flowchart of the MIC agent.

Figure S3 The flowchart of the PC agent.

Figure S4 The flowchart of the MM agent.

Figure S5 The flowchart of the TMM agent.

Figure S6 The pseudocode of the multi-scale agent-based model.

Movie S1 Simulation of myeloma growth in three-dimensional bone marrow space. Simulation conditions and details see Figure 2.

Movie S2 Simulation of stiffness profiles associated with myeloma growth in three-dimensional bone marrow space. Simulation conditions and details see Figure 2.

Movie S3 Spatial stiffness profile in three dimensional bone marrow space 400 hr after initiation. Simulation conditions and details see Figure 2.
Acknowledgments

The authors also acknowledge the Texas Advanced Computing Center (TACC) at The University of Texas at Austin for providing HPC resources that have contributed to the research results reported within this paper. URL: http://www.tacc.utexas.edu.

Author Contributions

Conceived and designed the experiments: JS LZ CC XZ. Performed the experiments: JS WZ DC JW BJ. Analyzed the data: JS. Contributed reagents/materials/analysis tools: DC JW. Wrote the paper: JS LZ CC XZ.

References

1. Chang CC, Schur BC, Kampalath B, Lindholm P, Becker CG, et al. (2001) A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry. Med Pathol 14: 1015–1021.
2. Joe Connay C-CC (2008) Determining the phenotype of clonotypic B-lymphocytes in multiple myeloma by flow cytometry. Arch Pathol Lab Med in press.
3. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Determination of the phenotype of clonotypic B-lymphocytes in multiple myeloma by flow cytometry. Arch Pathol Lab Med in press.
4. Matsui W, Wang Q, Barber JP, Berman S, Smith BD, et al. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190–197.
5. Velderrain J, Hutchinson A, Bhandarkar K, Mazumder A, Vesole D, et al. (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 203: 1859–1865.
6. Pilarski LM, Seegerer K, Coupland RW, Edsperer A, Keats JJ, et al. (2002) Leukemia B cells clonally identical to myeloma plasma cells are myelomagenic in NOB/SCID mice. Exp Hematol 30: 221–228.
7. Caers J, Van Valkenborgh E, Menu E, Van Camp B, Vanderkerken K (2008) Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 95: 301–313.
8. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwarz JM, Jones E, et al. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 104: 4049–4053.
9. Ghosh N, Matsui W (2006) Cancer stem cells in multiple myeloma. Cancer Lett. 250: 289–290.
10. Huff CA, Matsui W (2008) Multiple myeloma cancer stem cells. J Clin Oncol 26: 2895–2900.
11. Wicha MS, Liu S, Donut G (2006) Cancer stem cells: an old idea—a paradigm shift. Nat Rev Cancer 6: 761–772.
12. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367: 645–648.
13. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275–284.
14. Blame J, Rosinol L (2009) Changing paradigms in the treatment of multiple myeloma. Haematologica 94: 163–166.
15. Podor K, Tai YT, Hidolshima T, Valtz S, Richardson PG, et al. (2009) Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 14: 99–127.
16. Bensinger WI (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23: 442–448.
17. Feng Y, Oelke G, Choi DS, Wen J, Hu J, et al. (2010) Unique biomechanical interactions between myeloma cells and bone marrow stromal cells. Proc Natl Acad Sci U S A 107: 148–156.
18. Feng Y, Wen J, Mike P, Choi DS, Eshoa C, et al. (2010) Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Blood 115: 1289–1296.
19. Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 325: 1670–1673.
20. Kumar S, Weaver VM (2009) Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 28: 113–127.
21. Nefedova Y, Landowski TH, Dalton WS (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17: 1175–1182.
22. Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513–520.
23. Calabrese C, Poppleton H, Kowach M, Hogg TL, Fuller C, et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69–82.
24. Anderson KC (2007) Targeted therapy of multiple myeloma based upon tumor microenvironmental interactions. Exp Hematol 35: 155–162.
25. Lozoya OA, Waithier E, Turner RA, Barbier C, Prestwich GD, et al. (2011) Regulation of hepatic stem/progenitor phenotype by microenvironment stiffness in hydrogel models of the human liver stem cell niche. Biomaterials 32: 7389–7402.
26. Serban MA, Scott A, Prestwich GD (2001) Use of Hyaluronan-Derived Hydrogels for Three-Dimensional Cell Culture and Tumor Xenografts. Current Protocols in Cell Biology: John Wiley & Sons, Inc.
27. Azab AK, Rammels JM, Pintilleles C, Moreau A-S, Azab F, et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341–4351.
28. Ganguly R, Parik JK (2006) Mathematical model for the cancer stem cell hypothesis. Cell Prog 39: 3–14.
29. Boman BM, Wicha MS, Fields JZ, Ranquist OA (2007) Symmetric division of cancer stem cells—a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther 81: 893–898.
30. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic myeloid leukemia. Nature 435: 1267–1270.
31. Zhu X, Zheo XB, Lewis MT, Xia L, and Wong STG (2010) Cancer stem cell niche, niche and EGFR, decide tumor development and treatment response: A bio-computational Simulation Study. Journal of theoretical biology: in press.
32. Stepchenko BM, Schaff JC, Carson JH, Loew LM (2002) Computational cell biology: spatiotemporal simulation of cellular events. Annual review of biophysics and biomolecular structure 31: 423–441.
33. Su J, Zapata P, Chen C-C, Meredith JC (2009) Local cell metrics: a novel method for analysis of cell-cell interactions. BMC Bioinformatics 10: 350.
34. Souza GR, Molina JR, Raphael RM, Ozsawa MG, Stark DJ, et al. (2010) Three-dimensional tissue culture based on magnetic cell levitation. Nat Nanotechnol 5: 291–296.
35. Hirschmann-Jac C, Foster AE, Wolf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14226–14231.
36. Wen J, Feng Y, Huang W, Chen H, Liao B, et al. (2010) Enhanced antamyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 34: 85–92.
37. Keith CT, Borisy AX, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71–78.
38. Zhao L, Wenges MG, Au JL (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994–8004.
39. Wen J, Cheng HY, Feng Y, Rice L, Liu S, et al. (2008) P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140: 169–180.
40. Lowie S, Münchetz H (1926) Effect of combinations: mathematical basis of problem. Arch Exp Pathol Pharmacol 114: 313–326.
41. Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. Journal of Pharmacology and Experimental Therapeutics 319: 1–7.
42. Alon U (2006) An introduction to system biology: Disgn principles of biological circuits. Boca Raton, FL: Taylor and Francis group.
43. Segovia-Juarez JL, Ganguli S, Kirschner D (2004) Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J Theor Biol 231: 357–376.
44. Alarcon T, Byrne HM, Maini PK (2004) A mathematical model of the effects of hypoxia on the cell-cycle of normal and cancer cells. J Theor Biol 229: 395–411.
45. Zhang L, Aihale CA, Deaoboc DS (2007) Development of a three-dimensional multiscale agent-based tumor model: simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. J Theor Biol 244: 96–107.
46. Jakubekova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, et al. (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117: 4409–4419.
47. Shabaneh TB, Downs SL, Goddard AL, Screen M, Lucas MM, et al. (2013) Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib. PLoS ONE 8: e56954.